<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Trautmann, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DURATION-3 Trial Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">Three-year data from the Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Metformin Alone or in Combination With Sulfonylurea trial [DURATION-3; NCT00641056] have confirmed previously reported 26- and 84-week results demonstrating the superiority of the exenatide regimen for glycemic and weight control, and lowered risk of hypoglycemia [Diamant M et al. Lancet 2010; Diamant M et al. Diabetes Care 2012].</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>